Rhythm Pharmaceuticals Inc [RYTM] stock is trading at $112.52, down -0.92%. An important factor to consider is whether the stock is rising or falling in short-term value. The RYTM shares have gain 6.98% over the last week, with a monthly amount glided 17.34%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] stock has seen the most recent analyst activity on November 25, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $136. Previously, Oppenheimer downgraded its rating to Perform on November 05, 2025. On July 10, 2025, Goldman initiated with a Buy rating and assigned a price target of $97 on the stock. Leerink Partners started tracking the stock assigning an Outperform rating and suggested a price target of $88 on July 07, 2025. BofA Securities upgraded its rating to a Buy but $63 remained the price target by the analyst firm on April 07, 2025. In a note dated January 02, 2025, Jefferies initiated a Buy rating and provided a target price of $80 on this stock.
Rhythm Pharmaceuticals Inc [RYTM] stock has fluctuated between $45.90 and $122.20 over the past year. Currently, Wall Street analysts expect the stock to reach $135 within the next 12 months. Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] shares were valued at $112.52 at the most recent close of the market. An investor can expect a potential return of 19.98% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] reported sales of 174.33M for the trailing twelve months, which represents a growth of 54.28%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.07%, Pretax Profit Margin comes in at -1.1%, and Net Profit Margin reading is -1.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -1.26 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 110.49 points at the first support level, and at 108.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 115.44, and for the 2nd resistance point, it is at 118.37.
Ratios To Look Out For
For context, Rhythm Pharmaceuticals Inc’s Current Ratio is 4.75. On the other hand, the Quick Ratio is 4.53, and the Cash Ratio is 0.5. Considering the valuation of this stock, the price to sales ratio is 43.07, the price to book ratio is 50.42.
Transactions by insiders
Recent insider trading involved Cramer Pamela J., Chief Human Resources Officer, that happened on Dec 11 ’25 when 3350.0 shares were sold. Officer, PAMELA CRAMER completed a deal on Dec 11 ’25 to buy 3350.0 shares. Meanwhile, Chief Human Resources Officer Cramer Pamela J. sold 3350.0 shares on Nov 20 ’25.
